← BioNTech SE (BNTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
BioNTech SE (BNTX)
Biological Products, (No Diagnostic Substances) · market cap $25.2B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03
Earnings
Pipeline
20
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
BioNTech SE (BNTX) is a German multinational biotech with 7,807 employees and a ~$22.8B market cap, trading at ~$93.53. The company operates a broad pipeline spanning oncology and infectious disease, with its mRNA COVID-19 franchise (BNT162b2 family) as the established commercial anchor and Pumitamig in Phase 3 for extensive-stage small-cell lung cancer as the lead oncology catalyst. A Phase 3 readout was noted as positive in June 2026, and multiple near-term catalysts are clustered in H2 2026.
The catalyst path
- 2026-11-03Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Pumitamig | Phase 3 | Extensive-stage Small-cell Lung Cancer |
| BNT329 | Phase 2 | Advanced Solid Cancers |
| BNT326 | Phase 2 | Advanced Solid Tumor |
| BNT162b3 | Phase 2 | Covid-19 |
| BNT111 | Phase 2 | Melanoma Stage III |
| BNT162b2 | Phase 3 | SARS-CoV-2 Infection |
| BNT113 | Phase 3 | Unresectable Head and Neck Squamous Cell Carcinoma |
| BNT314 | Phase 2 | Metastatic Colorectal Cancer |
| bivalent BNT162b2 (original/Omi BA.4/BA.5) | Phase 2 | Influenza, Human |
| BNT162b2s01 | Phase 2 | COVID-19 |
| BNT162b1 | Phase 3 | SARS-CoV-2 Infection |
| BNT327 | Phase 2 | Non-small Cell Lung Cancer |
| BNT142 | Phase 2 | Solid Tumor |
| Biological/Vaccine: BNT162b2 10mcg | Phase 3 | SARS-CoV-2 Infection, COVID-19 |
| BNT162b2 OMI | Phase 3 | SARS-CoV-2 Infection |
| BNT3212 | Phase 2 | Advanced Solid Tumor |
| BNT162b2 (Omi XBB.1.5) | Phase 3 | SARS-CoV-2 Infection |
| BNT162b5 Bivalent (WT/OMI BA.2) | Phase 3 | SARS-CoV-2 Infection |
| Seasonal Inactivated Influenza Vaccine | Phase 3 | SARS-CoV-2 Infection |
| RO7198457 intravenous (IV) | Phase 2 | Colorectal Cancer Stage II |
Price & technical context
3-month
-0.7%
6-month
+8.3%
12-month
-1.8%
52-wk range
$83.89–$119.34
vs 50-day MA
-1.6%
vs 200-day MA
-0.9%
Realized vol
45.5%
Max drawdown
-33.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BNTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.